Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5

Abstract

The functional role of IGFBP5 in breast cancer is complicated. Experimental and bioinformatics studies have shown that IGFBP5 is targeted by miR-140-5p and miR-193b, although this has not yet been proven in clinical samples. The aim of this study was to evaluate the expression of miR-140-5p and miR-193b in breast cancer and adjacent normal tissue and assess its correlation with IGFBP5 and the clinicopathological characteristics of the tumors. IGFBP5 protein expression was analyzed immunohistochemically and IGFBP5, miR-140 and miR-193b mRNA expression levels were analyzed with real-time RT-PCR. Tumor tissue had higher miR-140-5p expression than adjacent normal tissue (p = 0.015). Samples with no immunohistochemical staining for IGFBP5 showed increased miR-140-5p expression (p = 0.009). miR-140-5p expression was elevated in invasive ductal carcinomas (p = 0.002), whereas basal-like tumors had decreased expression of miR-140-5p compared to other tumors (p = 0.008). Lymph node-positive samples showed an approximately 13-fold increase in miR-140-5p expression compared to lymph node-negative tissue (p = 0.049). These findings suggest that miR-140-5p, but not miR-193b, could be an important determinant of IGFBP5 expression and clinical phenotype in breast cancer patients. Further studies are needed to clarify the expressional regulation of IGFBP5 by miR-140-5p.

RETRACTED ARTICLE: microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5

“…Consistent with this, Güllü et al [23] reported that, immunohistochemically, IGFBP5-negative breast cancer samples have a significantly increased expression of miR-140. However, their results indicated that miR-140 is dramatically increased in the breast cancer samples [23]. This different role of the same miRNA may depend on the types of cell and tissue, and time point [40].…”

“…Malzkorn et al [22] reported that miR-140 is one of the increased microRNA candidates in glioma progression from grade II to grade IV. Güllü et al [23] also found that miR-140 is overexpressed in the invasive ductal breast cancer tissues and lymph node-positive samples. Based on the above studies, we intend to investigate the impact and mechanism of miR-140 on CRC progression.…”

MicroRNA-140 represses glioma growth and metastasis by directly targeting ADAM9

“…Reduced expression levels of miR-140 has been demonstrated in pancreatic duct adenocarcinoma (29), lung (30,31), colorectal (32), ovarian (33), esophageal (34) and tongue cancer (35). However, miR-140 also has been found upregulated in spinal chordoma (36) and breast cancer (37). These studies suggested that expression of miR-140 has tissue specificity.…”

Selecting molecular therapeutic drug targets based on the expression profiles of intrahepatic cholangiocarcinomas and miRNA-mRNA regulatory networks

“…Fisher's exact test was used to calculate the p-value of each drug's regulation of each module, and the p-values were converted into statistical scores [statistical score = -log(Fisher's p-value)]. cells (15) and plays important roles in human uterine leiomyoma cells, breast cancer, urothelial carcinoma and papillary thyroid carcinoma (16)(17)(18). The role of tumor metabolism has also been appreciated in recent years.…”